Dual engineered bacteria improve inflammatory bowel disease in mice

DOI: https://doi.org/10.1007/s00253-024-13163-w
IF: 5
2024-05-14
Applied Microbiology and Biotechnology
Abstract:Currently, there are many different therapies available for inflammatory bowel disease (IBD), including engineered live bacterial therapeutics. However, most of these studies focus on producing a single therapeutic drug using individual bacteria, which may cause inefficacy. The use of dual drugs can enhance therapeutic effects. However, expressing multiple therapeutic drugs in one bacterial chassis increases the burden on the bacterium and hinders good secretion and expression. Therefore, a dual-bacterial, dual-drug expression system allows for the introduction of two probiotic chassis and enhances both therapeutic and probiotic effects. In this study, we constructed a dual bacterial system to simultaneously neutralize pro-inflammatory factors and enhance the anti-inflammatory pathway. These bacteria for therapy consist of Escherichia coli Nissle 1917 that expressed and secreted anti-TNF-α nanobody and IL-10, respectively. The oral administration of genetically engineered bacteria led to a decrease in inflammatory cell infiltration in colon and a reduction in the levels of pro-inflammatory cytokines. Additionally, the administration of engineered bacteria did not markedly aggravate gut fibrosis and had a moderating effect on intestinal microbes. This system proposes a dual-engineered bacterial drug combination treatment therapy for inflammatory bowel disease, which provides a new approach to intervene and treat IBD.
biotechnology & applied microbiology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: how to treat inflammatory bowel disease (IBD) more effectively through a dual - engineered bacteria system. Specifically, the authors constructed a dual - bacteria, dual - drug expression system to simultaneously neutralize pro - inflammatory factors and enhance anti - inflammatory pathways. This system consists of two genetically engineered Escherichia coli Nissle 1917 (EcN), one expressing and secreting anti - TNF - α nanobodies and the other expressing and secreting IL - 10. ### Research Background and Problems Currently, although there are many different therapies for treating IBD, including the use of engineered live - bacteria therapies, most studies focus on using a single bacterium to produce a single therapeutic drug, which may lead to poor efficacy. Using two drugs can enhance the therapeutic effect, but expressing multiple therapeutic drugs in a single - bacterium chassis will increase the burden on the bacteria and affect good secretion and expression. Therefore, adopting a dual - bacteria system can introduce two probiotic chassis, thereby enhancing the therapeutic and probiotic effects. ### Main Problems 1. **Limitations of Single - Drug Therapies**: Most studies focus on a single bacterium producing a single therapeutic drug, which may lead to poor efficacy. 2. **Challenges of Multi - Drug Expression**: Expressing multiple drugs in a single bacterium will increase the burden on the bacteria and affect secretion and expression. 3. **The Need to Improve the Efficacy of IBD Treatment**: There is a need to develop more effective treatment methods to improve the symptoms of IBD patients. ### Solutions The authors constructed a dual - bacteria system that expresses and secretes anti - TNF - α nanobodies and IL - 10 respectively to simultaneously neutralize pro - inflammatory factors and enhance anti - inflammatory pathways. Through oral administration, this dual - engineered bacteria system can reduce the infiltration of inflammatory cells in the colon and decrease the levels of pro - inflammatory cytokines. In addition, this system does not significantly aggravate intestinal fibrosis and has a regulatory effect on the gut microbiota. ### Experimental Results - **Body Weight Changes**: Mice treated with the dual - engineered bacteria had a smaller decrease in body weight during DSS treatment. - **Colon Length**: The colon length of mice in the dual - engineered bacteria treatment group was significantly increased, indicating that the disease progression was alleviated. - **Histological Evaluation**: The results of HE staining showed that the infiltration of inflammatory cells in the colon of mice in the dual - engineered bacteria treatment group was reduced, and good rectal integrity was maintained. - **Cytokine Levels**: The concentrations of anti - TNF - α nanobodies and IL - 10 in the feces of mice in the dual - engineered bacteria treatment group were significantly increased, and the levels of pro - inflammatory cytokines in the colon were decreased. In conclusion, this study proposes a new dual - engineered bacteria drug combination treatment method, providing new ideas for intervening in and treating IBD.